Проблемы эффективности и безопасности вторичной профилактики ишемического инсульта
https://doi.org/10.17650/1818-8338-2013-2-73-80
Аннотация
Ишемический инсульт (ИИ) – тяжелое заболевание, ассоциированное с высокой летальностью и стойкой инвалидизацией.Перенесенный ИИ связан с резким повышением риска повторного ИИ. Эффективным направлением предупреждения повторного ИИ является антитромбоцитарная терапия. Особой эффективностью обладает ацетилсалициловая кислота, применение которой в виде кишечнорастворимой лекарственной формы позволяет снизить риск развития поражения слизистой желудка. Рассматриваются возможности применения других антиагрегантов и непрямых антикоагулянтов.
Ключевые слова
Об авторах
П. Р. КамчатновРоссия
А. А. Кабанов
Россия
Список литературы
1. Гусев Е.И., Скворцова В.И., Стаховская Л.В. Эпидемиология инсульта в России. Журн неврол и психиатр 2003;(прил 8):4–9.
2. Sacco R.L., Adams R., Albers G. et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke 2006;37(2):577–617.
3. Coull A.J., Lovett J.K., Rothwell P.M.; Oxford Vascular Study. Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services. BMJ 2004;328(7435):326.
4. Lovett J.K., Coull A.J., Rothwell P.M. Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. Neurology 2004;62(4):569–73.
5. Жетишев Р.Р., Камчатнов П.Р., Михайлова Н.А., Иващенко А.Р. Асимптомный инсульт. Журн неврол
6. и психиатр 2013;113(3 прил 2);53–7.
7. Vermeer S.E., Hollander M., van Dijk E.J. et al. Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. Stroke 2003;34(5):1126–9.
8. Фрис Я.Е., Камчатнов П.Р., Шелякина Л.А. Информированность населения о факторах риска сосудистых заболеваний головного мозга и клинических проявлений инсульта. Журн неврол и психиатр 2010;9(2):3–12.
9. Brott T.G., Halperin J.L., Abbara S. et al. ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: executive summary. J Am Coll Cardiol 2011;57(8):1002–44.
10. Lip G.Y., Kamath S., Hart R.G. ABC of antithrombotic therapy: Antithrombotic therapy for cerebrovascular disorders. BMJ 2002;325(7373):1161–3.
11. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials
12. of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324(7329):71–86.
13. Antithrombotic Trialists' (ATT) Collaboration, Baigent C., Blackwell L., Collins R. et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373(9678):1849–60.
14. Wang Y., Wang Y., Zhao X. et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 2013;369(1):11–9.
15. Chen Z.M.,Sandercock P., Pan H.C. et al. Indications for early aspirin use in acute ischemic stroke : A combined analysis of40 000 randomized patients from the chinese acute stroke trial and the international stroke trial.On behalf of the CASTand IST collaborative groups. Stroke2000;31(6):1240–9.
16. Rodríguez L.A., Cea-Soriano L., Martín-Merino E., Johansson S. Discontinuation of low dose aspirin and risk of myocardial infarction: case-control study in UK primary care. BMJ 2011;343:d4094.
17. Wolff T., Miller T., Ko S. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2009;150(6):405–10.
18. Профилактика сердечно-сосудистых заболеваний в клинической практике. Рекомендации Европейского общества кардиологов (пересмотр 2012 г.). Рос кардиол журн 2012;4(96 прил 2):1–84.
19. Charlot M., Grove E.L., Hansen P.R. et al. Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ 2011;342:d2690.
20. Miner P.B.Jr., Fort J.G., Zhang Y. Intragastric acidity and omeprazole exposure during dosing with either PA32540 (entericcoated aspirin 325 mg + immediaterelease omeprazole 40 mg) or entericcoated aspirin 325 mg + enteric-coated omeprazole 40 mg – a randomised, phase 1, crossover study. Aliment Pharmacol Ther 2013;38(1):62–71.
21. Williams B., Poulter N.R., Brown M.J. et al.; BHS guidelines working party, for the British Hypertension Society. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004;328(7440):634–40.
22. Felmeden D.C., Lip G.Y. Antithrombotic therapy in hypertension: a Cochrane Systematic review. J Hum Hypertens 2005;19(3):185–96.
23. Berrouschot J., Schwetlick B., von Twickel G. et al. Aspirin resistance in secondary stroke prevention. Acta Neurol Scand 2006;113(1):31–5.
24. Michelson A.D., Cattaneo M., Eikelboom J.W. et al. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 2005;3(6):1309–11.
25. Sacco R.L., Adams R., Albers G. et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Circulation 2006;113(10);e409–49.
26. Gage B.F., Waterman A.D., Shannon W. et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285(22):2864–70.
27. Lip G.Y., Nieuwlaat R., Pisters R. et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 2010;137(2):263–72.
28. Hippisley-Cox J., Coupland C., Brindle P. Derivation and validation of QStroke score for predicting risk of ischemic stroke in primary care and comparison with other risk scores: a prospective open cohort study. BMJ 2013;346:f2573.
29. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation:analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154(13):1449–57.
30. Lane D.A., Lip G.Y. Use of the CHA(2) DS(2)-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in nonvalvular atrial fibrillation. Circulation 2012;126(7):860–5.
31. Chimowitz M.I., Lynn M.J., Howlett-Smith H. et al.; Warfarin-Aspirin Symptomatic Intracranial Disease Trial Investigators. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005;352(13):1305–16.
32. Donzé J., Clair C., Hug B. et al. Risk of falls and major bleeds in patients on oral anticoagulation
33. therapy. Am J Med 2012;125(8):773–8.
34. De Schryver E.L., van Gijn J., Kappelle L.J. et al. Non-adherence to aspirin or oral anticoagulants in secondary prevention after ischemic stroke. J Neurol 2005;252(11):1316–21.
35. De Schryver E.L., Algra A., van Gijn J. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. Cochrane Database Syst Rev 2006;(2):CD001820.
36. Sacco R.L., Diener H.C., Yusuf S. et al. Aspirin and extended-release dipyridamol versus clopidogrel for recurrent stroke. N Eng J Med 2008;359(12):1238–51.
37. Offman E., Schobelock M.J., Brickl R. et al. Pharmacokinetics and pharmacodynamics of the antiplatelet combination aspirin (acetylsalicylic acid) plus extended-release dipyridamole are not altered by coadministration with the potent CYP2C19 inhibitor omeprazole. Am J Cardiovasc
38. Drugs 2013;13(2):113–20.
39. Diener H.C., Bogousslavsky J., Brass L.M. et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischemic stroke or transient ischemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004;364(9431):331–7.
40. Wang T.H., Bhatt D.L., Fox K.A. et al. An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. Eur Heart J 2007;28(18):2200–7.
41. Keller T.T., Squizzato A., Middeldorp S. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease. Cochrane Database Syst Rev 2007;(3):CD005158.
42. Willmot M., Zhao L., Heptinstall S., Bath P. Triple antiplatelet therapy for secondary prevention of recurrent ischemic stroke. J Stroke Cerebrovasc Dis 2004;13(3):138–40.
43. Niinuma Y., Saito T., Takahashi M. et al. Functional characterization of 32 CYP2C9 allelic variants. Pharmacogenomics J 2013;doi:10.1038/tpj.2013.22. [Epub ahead of print].
44. Kim Y.B., Ko M.J., Lee D.G. et al. CYP2C9 mutation affecting the individual variability of warfarin dose requirement. Ann Rehabil Med 2012;36(6):857–60.
45. Castro T.A., Heineck I. Interventions to improve anticoagulation with warfarin. Ther Drug Monit 2012;34(2):209–16.
46. Uno T., Sugimoto K., Sugawara K., Tateishi T. The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole. Ther Drug Monit 2008;30(3):276–81.
47. Holbrook A.M., Pereira J.A., Labiris R. et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005;165(10):1095–106.
48. Armstrong M.J., Gronseth G., Anderson D.C. et al. Summary of evidencebased guideline: periprocedural management of antithrombotic medications in patients with ischemic cerebrovascular disease: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2013;80(22):2065–9.
Рецензия
Для цитирования:
Камчатнов П.Р., Кабанов А.А. Проблемы эффективности и безопасности вторичной профилактики ишемического инсульта. Клиницист. 2013;7(2):73-80. https://doi.org/10.17650/1818-8338-2013-2-73-80
For citation:
Kamchatnov P.R., Kabanov A.A. THE EFFICIENCY AND SAFETY OF SECONDARY PREVENTION OF ISCHEMIC STROKE. The Clinician. 2013;7(2):73-80. (In Russ.) https://doi.org/10.17650/1818-8338-2013-2-73-80